Abstract
The purpose of this study was to investigate whether the overall treatment time and completion rates of chemotherapy were predictive factors for the survival rates in patients with squamous cell carcinoma of the head and neck (SCCHN) who were treated with concurrent chemoradiotherapy (CCRT) using hyperfractionated radiotherapy (RT) and daily carboplatin. The number of intermission days of RT were as follows; 0 (n = 37), 1–5 (n = 8), 6–10 (n = 12) and ≥11 (n = 12), and the days of RT without carboplatin; 0 (n = 27), 1–5 (n = 13), 6–10 (n = 13) and ≥7 (n = 16). The overall treatment time (≤48 vs ≥49 days) was a significant prognostic factor for the local control, disease-free survival and overall survival rates. The completion rate of chemotherapy, as the number of days of RT without carboplatin, was not a significant factor affecting any of the survival rates. In discussion, the strengths of the present study contain that all the patients were treated with 72 Gy delivered as 1.2 Gy twice daily, and received concurrent chemotherapy comprising daily carboplatin as a radio-sensitizer. Based on the results, the completion rate of chemotherapy may have a lower impact on the local control rate in comparison with the overall treatment time. We believe that when a treatment interruption is needed because of the acute toxicities, hyperfractionated RT should be resumed as soon as possible independently while continuing the break of daily carboplatin. The overall treatment time influenced the clinical outcomes in SCCHN patients treated with hyperfractionated CCRT using carboplatin, while the impact of the completion rates of daily carboplatin was limited. Sixty-nine consecutive patients with SCCHN were initially treated with definitive CCRT and were retrospectively analyzed. All 69 patients were treated with CCRT using hyperfractionated RT of 72 Gy in 60 fractions and daily carboplatin (25 mg/m2). The patients treated with other chemotherapeutic regimens or induction chemotherapy were excluded. On the intermission days of the RT, carboplatin was not prescribed. After the intermission, CCRT using RT plus daily carboplatin or RT alone was resumed.
Highlights
The prolongation of the overall treatment time of radiotherapy (RT) results in poorer clinical outcomes inFujii et al SpringerPlus (2015) 4:446 significant improvement in the local control of head and neck cancers treated with twice-daily fractionation over once daily fractions (Horiot et al 1992)
There have been only a few reports that have investigated whether the overall treatment time or completion rate of concurrent chemotherapy is a prognostic factor in SCCHN patients treated with concurrent chemoradiotherapy (CCRT) using conventional fractionated RT (Pignon et al 2000; Langendijk et al 2004)
To the best of our knowledge, there have been no reports that have evaluated the prognostic impact of the overall treatment time or completion rate of concurrent chemotherapy in patients treated with CCRT using hyperfractionated RT
Summary
The prolongation of the overall treatment time of radiotherapy (RT) results in poorer clinical outcomes inFujii et al SpringerPlus (2015) 4:446 significant improvement in the local control of head and neck cancers treated with twice-daily fractionation over once daily fractions (Horiot et al 1992). In the meta-analyses of head and neck cancers, the survival benefit of chemotherapy given synchronously with RT has been demonstrated (Munro 1995) In this context, concurrent chemoradiotherapy (CCRT) and hyperfractionated RT have been used for SCCHN, and the efficacy of CCRT using hyperfractionated RT was confirmed in a meta-analysis (Budach et al 2006). To the best of our knowledge, there have been no reports that have evaluated the prognostic impact of the overall treatment time or completion rate of concurrent chemotherapy in patients treated with CCRT using hyperfractionated RT.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
